Trinity Biotech PLC 6-K, filed Jan 25, 2022
Trinity Biotech PLC (TRIB)
6-K
2022-01-25
For: 2022-01-25
View Original
Added on
April 12, 2026
About this 6-K
Trinity Biotech PLC filed this 6-K on January 25, 2022.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2022
TRINITY BIOTECH PLC
(Name of Registrant)
IDA Business Park
Bray, Co. Wicklow, Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
EXPLANATORY NOTE
On January 25, 2022, Trinity Biotech plc (the “Company”) held an extraordinary general meeting of shareholders to approve a refinancing transaction with respect to substantially all of the
outstanding $99.9 million of exchangeable senior notes issued by its subsidiary, Trinity Biotech Investment Limited, and guaranteed by the Company. At the extraordinary general meeting, the Company’s shareholders approved the refinancing
transaction and three related resolutions, with each resolution being approved by at least 97% of votes cast.
A copy of the press release announcing the results of the extraordinary general meeting is attached hereto as Exhibit 99.1 and
incorporated herein by reference
EXHIBIT INDEX
|
Exhibit
|
|
Description
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
| TRINITY BIOTECH PLC | |||
| (Registrant) | |||
|
|
By:
|
/s/ John Gillard | |
| John Gillard | |||
| Chief Financial Officer | |||
Date: 25 January 2022
Exhibit 99.1
January 25, 2022
|
Contact:
|
Trinity Biotech plc
|
Lytham Partners, LLC
|
|
|
John Gillard
|
Joe Diaz
|
|
|
(353)-1-2769800
|
(1)-602-889-9700
|
| E-mail: investorrelations@trinitybiotech.com |
Trinity Biotech Announces That Its Shareholders Have
Approved All of the Four Resolutions That Were the Subject
of the EGM Held on January 25, 2022
DUBLIN, Ireland (January 25, 2022)…. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care
and clinical laboratory markets, today announced the results of an Extraordinary General Meeting (EGM).
EGM Results
As previously announced, the Company has entered into refinancing transactions (the “Refinancing”) with respect to substantially all of the outstanding $99.9 million of exchangeable senior notes
issued by our subsidiary, Trinity Biotech Investment Limited, and guaranteed by the Company. The Refinancing is conditional on, among other things, the approval by the Company’s shareholders of the new term loan, an increase in the authorized
share capital of the Company, authority for the board to issue ordinary shares of the Company without limitation under Irish law, and the issuance of warrants to the lender in the Refinancing, with such approvals being more fully set out in the
four shareholder resolutions included in Notice of EGM issued on 23 December, 2021.
At the EGM, the Company’s shareholders approved all of the four resolutions put to the meeting, with each resolution being approved by at least 97% of votes cast.
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical
laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the
United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.